JP7190612B2 - 置換ピペリジン化合物及びその用途 - Google Patents

置換ピペリジン化合物及びその用途 Download PDF

Info

Publication number
JP7190612B2
JP7190612B2 JP2022536446A JP2022536446A JP7190612B2 JP 7190612 B2 JP7190612 B2 JP 7190612B2 JP 2022536446 A JP2022536446 A JP 2022536446A JP 2022536446 A JP2022536446 A JP 2022536446A JP 7190612 B2 JP7190612 B2 JP 7190612B2
Authority
JP
Japan
Prior art keywords
mmol
added
compound
azabicyclo
methanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022536446A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022014680A5 (enExample
JPWO2022014680A1 (enExample
Inventor
融 吉田
陽一 北
真 小竹
啓一 反町
俊行 大房
貴史 元木
太郎 浅羽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of JPWO2022014680A1 publication Critical patent/JPWO2022014680A1/ja
Application granted granted Critical
Publication of JP7190612B2 publication Critical patent/JP7190612B2/ja
Publication of JPWO2022014680A5 publication Critical patent/JPWO2022014680A5/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pain & Pain Management (AREA)
JP2022536446A 2020-07-17 2021-07-15 置換ピペリジン化合物及びその用途 Active JP7190612B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020122864 2020-07-17
JP2020122864 2020-07-17
PCT/JP2021/026649 WO2022014680A1 (ja) 2020-07-17 2021-07-15 置換ピペリジン化合物及びその用途

Publications (3)

Publication Number Publication Date
JPWO2022014680A1 JPWO2022014680A1 (enExample) 2022-01-20
JP7190612B2 true JP7190612B2 (ja) 2022-12-15
JPWO2022014680A5 JPWO2022014680A5 (enExample) 2022-12-16

Family

ID=79291962

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022536446A Active JP7190612B2 (ja) 2020-07-17 2021-07-15 置換ピペリジン化合物及びその用途

Country Status (19)

Country Link
US (1) US11479552B2 (enExample)
EP (1) EP4151277A4 (enExample)
JP (1) JP7190612B2 (enExample)
KR (1) KR20230040953A (enExample)
CN (3) CN115884971B (enExample)
AR (1) AR122973A1 (enExample)
AU (1) AU2021308053A1 (enExample)
BR (1) BR112022026161A2 (enExample)
CA (1) CA3187835A1 (enExample)
CL (1) CL2022003666A1 (enExample)
CO (1) CO2022018446A2 (enExample)
IL (1) IL299125B1 (enExample)
MX (1) MX2022016388A (enExample)
PE (1) PE20231103A1 (enExample)
PH (1) PH12022553488A1 (enExample)
TW (1) TWI888599B (enExample)
UA (1) UA129636C2 (enExample)
WO (1) WO2022014680A1 (enExample)
ZA (1) ZA202213562B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI4065585T1 (sl) 2019-11-25 2025-11-28 Alkermes, Inc. Substituirane makrociklične spojine ter z njimi povezani postopki zdravljenja
US12006330B2 (en) 2020-12-21 2024-06-11 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
US20250051322A1 (en) * 2022-01-14 2025-02-13 Eisai R&D Management Co., Ltd. Crystal of substituted piperidine compound, salts of substituted piperidine compound, and crystals thereof
JP7591592B2 (ja) * 2022-01-14 2024-11-28 エーザイ・アール・アンド・ディー・マネジメント株式会社 置換ピペリジン化合物を含有する医薬
IL319940A (en) * 2022-10-07 2025-05-01 Kissei Pharmaceutical Cyclopentane compound
CN120129521A (zh) * 2022-10-31 2025-06-10 武田药品工业株式会社 食欲素2型受体激动剂的给药
JPWO2024128305A1 (enExample) 2022-12-16 2024-06-20
TW202502342A (zh) 2023-06-02 2025-01-16 日商武田藥品工業股份有限公司 食慾素２受體促效劑用於改善睡眠期間之呼吸功能的用途
WO2025124698A1 (en) 2023-12-12 2025-06-19 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators
WO2025132542A1 (en) 2023-12-19 2025-06-26 Idorsia Pharmaceuticals Ltd Macrocyclic orexin agonists
WO2025137359A1 (en) 2023-12-20 2025-06-26 Eisai R&D Management Co., Ltd. Assay methods to identify a disease
WO2025229493A1 (en) 2024-04-29 2025-11-06 Takeda Pharmaceutical Company Limited Dosing of orexin type 2 receptor agonists

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005028438A1 (ja) 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. 新規ピペリジン誘導体
JP2008517032A (ja) 2004-10-20 2008-05-22 ノイロサーチ アクティーゼルスカブ 新規なジアザ二環式アリール誘導体及びその医薬用途
JP2016512536A (ja) 2013-03-13 2016-04-28 ヤンセン ファーマシューティカ エヌ．ベー． 置換した７−アザビシクル及びオレキシン受容体調節因子としてのそれらの使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG34208A1 (en) 1995-03-01 1996-12-06 Guy Andrew Vaz Blast and fragment resistant polyurethane boot sole for safety footwear
WO1996034877A1 (en) 1995-05-05 1996-11-07 Human Genome Sciences, Inc. Human neuropeptide receptor
US6309854B1 (en) 1996-12-17 2001-10-30 Smithkline Beecham Corporation Polynucleotides encoding ligands of the neuropeptide receptor HFGAN72
US6159605A (en) 1997-02-18 2000-12-12 Dainichiseika Color & Chemicals Mfg. Co., Ltd. Ink-jet recording sheet
US6020157A (en) 1997-04-30 2000-02-01 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72X receptor
US5935814A (en) 1997-04-30 1999-08-10 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72Y receptor
US6166193A (en) 1997-07-25 2000-12-26 Board Of Regents, University Of Texas System Polynucleotides encoding MY1 receptor
KR100327888B1 (ko) 1999-07-14 2002-03-09 정숭렬 도로포장 파손촉진 시험장치의 무선제어 시스템
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005028438A1 (ja) 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. 新規ピペリジン誘導体
JP2008517032A (ja) 2004-10-20 2008-05-22 ノイロサーチ アクティーゼルスカブ 新規なジアザ二環式アリール誘導体及びその医薬用途
JP2016512536A (ja) 2013-03-13 2016-04-28 ヤンセン ファーマシューティカ エヌ．ベー． 置換した７−アザビシクル及びオレキシン受容体調節因子としてのそれらの使用

Also Published As

Publication number Publication date
PE20231103A1 (es) 2023-07-19
US20220017517A1 (en) 2022-01-20
CA3187835A1 (en) 2022-01-20
MX2022016388A (es) 2023-01-30
JPWO2022014680A1 (enExample) 2022-01-20
CL2022003666A1 (es) 2023-05-26
AR122973A1 (es) 2022-10-19
CN119258067A (zh) 2025-01-07
UA129636C2 (uk) 2025-06-18
CN115884971B (zh) 2024-11-05
AU2021308053A1 (en) 2023-02-02
ZA202213562B (en) 2023-10-25
IL299125A (en) 2023-02-01
CN119235864A (zh) 2025-01-03
PH12022553488A1 (en) 2024-04-22
KR20230040953A (ko) 2023-03-23
TW202216705A (zh) 2022-05-01
CN115884971A (zh) 2023-03-31
WO2022014680A1 (ja) 2022-01-20
EP4151277A1 (en) 2023-03-22
CO2022018446A2 (es) 2023-03-07
EP4151277A4 (en) 2024-06-26
IL299125B1 (en) 2025-11-01
TWI888599B (zh) 2025-07-01
US11479552B2 (en) 2022-10-25
BR112022026161A2 (pt) 2023-01-31

Similar Documents

Publication Publication Date Title
JP7190612B2 (ja) 置換ピペリジン化合物及びその用途
CN114025844B (zh) 蛋白酪氨酸磷酸酶抑制剂及其使用方法
TWI378101B (en) Pyridine derivatives and their use in the treatment of psychotic disorders
CN101657453A (zh) 作为PKC-θ抑制剂的嘌呤类
KR101800140B1 (ko) 벤조티아졸론 화합물
CN102325768A (zh) 治疗疼痛和其他疾病的化合物和方法
TW202432509A (zh) 對於食慾素-2受體拮抗劑之製備有用之方法及化合物、以及雜質少之萊博雷生
TW202012362A (zh) 稠合三環γ-胺基酸衍生物之組合物及其製備方法
EP4438602A1 (en) Crystal of substituted piperidine compound, salts of substituted piperidine compound, and crystals thereof
JP7591592B2 (ja) 置換ピペリジン化合物を含有する医薬
RU2840772C1 (ru) Замещенные пиперидиновые соединения и их применение
EA045865B1 (ru) Замещенные пиперидиновые соединения и их применение
TW202542144A (zh) 取代哌啶化合物及其用途
TW202340145A (zh) 氘化有機化合物及其用途
TW202333671A (zh) 氘化有機化合物及其用途
HK40083601A (en) Substituted piperidine compound and application thereof
HK40083601B (zh) 取代的哌啶化合物及其用途
JP2023518309A (ja) 糖尿病性網膜症の治療において使用するためのソルチリン拮抗薬
WO2025146480A1 (en) 2-azabicyclo[2.1.1]hexane derivatives useful in the treatment of mitochondrial disorders
JP2025526368A (ja) Ｉｒａｋ３のリガンド指向性分解分子としての置換ピラゾリル－ピリジニル化合物
KR20150047586A (ko) 베타-2-아드레날린수용체 효능제로서의 벤조티아졸론 화합물의 염
JPH09512836A (ja) 細胞付着抑制剤としての（−）−（３ｒ）−３−メチル−４−｛４−［４−（４−ピリジル）ピペラジン−１−イル］フェノキシ｝酪酸

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221026

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221026

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20221026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221028

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221115

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221205

R150 Certificate of patent or registration of utility model

Ref document number: 7190612

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250